Health 2.0 Europe: Over 35 Speakers from 15 Countries Already Confirmed

27 - 28 October 2011, Berlin, Germany.
Following the success of our first event in Paris in April 2010, the 2nd annual Health 2.0 Europe to hip Berlin. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offering. The 2nd edition will reconvene all the leaders and stakeholders in web 2.0 for health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

Health investor Esther Dyson to present on 'From Health to Wellness 2.0'
An active investor in technology start-ups with a keen interest in the potential of internet technology to change healthcare, Esther Dyson from EDventure Holdings will present on 'From Health to Wellness 2.0'. Her health technology investments include Medstory, sold to Microsoft in 2007, 23andMe, Habit Labs, Medscape, OrganizedWisdom, PatientsLikeMe and ReliefInsite.

Over 35 speakers already confirmed
Confirmed speakers also include:

  • Roberto ASCIONE, Publicis Healthware International, Italy
  • Alberto SANNA, Fondazione Centro San Raffaele, Italy
  • Gábor GYARMATI, Szinapszis Group, Hungary
  • Anna GYARMATI, KamaszPanasz, Hungary
  • Emma STANTON, Department of Health, UK
  • Chris COOPER, EPG Health Media, UK
  • Matt JAMESON EVANS, HealthUnlocked, UK
  • Tim RINGROSE, Networks in Health/Doctors.net.uk, UK,
  • Howard LAST, Active Medicine Ltd, UK
  • Jonathan BLOOR, DocCom, UK
  • Anatole MENON-JOHANSSON, SXT Health CIC, UK
  • Frank ANTWERPES, DocCheck, Germany
  • Michael ALVERS, Transinsight GmbH, Germany
  • Britta LANG, Cochrane Collaboration, Germany
  • Jorge Juan FERNANDEZ, Hospital Sant Joan de Déu, Spain
  • Frederic LLORDACHS, Doctoralia, Spain
  • Miguel CABRER, Medting, Spain
  • Bartho HENGST, KWF Kankerbestrijding, The Netherlands
  • René SIELHORST, Intenz, The Netherlands
  • Joris MOOLENAAR, IPPZ, The Netherlands
  • Robert HALKES, Drimpy, The Netherlands
  • Jasper TEN DAM, my Jellinek, The Netherlands
  • Marco VITULA, Diagnosia, Austria
  • Stephen COOK, 23 Gears Web Systems, Sweden
  • Anna OMSTEDT LINDGREN, MedUniverse, Sweden
  • Greg BIGGERS, Genomera, US
  • Pablo GRAIVER, TrialReach, UK/Israel
  • Dennis VAN ROOIJ, medCrowd, UK/The Netherlands
  • Laurent COUSSIRAT, The Mood Institute, France
  • Ulrich SCHULZE-ALTHOFF, Medisana Space Technologies GmbH, Germany
  • Roman SCHENK, Protegia GmbH, Germany
  • Rachel IREDALE, Cancer Genetics Story Bank, UK
  • Wouter TUIL, MijnZorgnet, NL
  • Roman RITTWEGER, Advisors in Healthcare
  • David Clifford, PatientsLikeMe, USA
  • Kai Sostmann, Charité University Hospital, Germany
  • Topi Hanhela, Pharmaceutical Information Centre, Finland

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...